← boardnext 2027-05
NRXP
ERX Pharmaceuticalsdistress 10/10 · high distress / dilution risk$4.29-4%today-7% from 52w high
Lead: Obesity & Overweight · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$7M
Runway
0.5 yrs
Shares 1y
+84%
Price & events
+83.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-4.2%
1D
+1.2%
1W
+14.1%
1M
+51.1%
3M
+97.7%
6M
+41.6%
1Y
+77.3%
2Y
-98.3%
5Y
-98.2%
All
Overview
- Market Cap
- $155.42M
- Volume
- 126.82K
- 52 Week Range
- $1.68 – $4.62
- Total Shares
- 36.23M
- Float Shares
- 31.23M
- Short %
- 13.15%
- % Held by Insiders
- 7.58%
- % Held by Institutions
- 17.54%
- RVOL
- 0.16x
- Beta
- 2.19
Pipeline stages · 1 programs
ERX1000
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 2 | ERX1000 | Obesity & Overweight | — | recruiting |
Catalyst news & presentations · 7
- 2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-07-21partnershipNRX-101 · DARPA selected proposal for negotiation of potential award for SPARC-TMS trialSEC 8-K
- 2026-02-17fda agreementNRX-100 · Type C FDA meeting provided path to NDA with real world data.SEC 8-K
- 2025-12-18partnershipRepaid $5.4M debt to Anson Funds via equity conversion, eliminating all balance sheet debt.SEC 8-K
- 2025-10-17partnershipHOPE Therapeutics acquired a strategic minority interest in Cohen, LLCSEC 8-K
- 2025-09-08partnershipCompleted acquisition of Dura Medical via subsidiary HOPE Therapeutics.SEC 8-K
- 2025-08-13fda agreementNRX-100 · FDA identified missing batch records and 6% ingredient difference; company will resubmit.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $42 (+879% upside) · 4 analysts
- 2026-05-05D. Boral CapitalBuy
- 2026-04-27Ascendiant CapitalBuy
- 2026-04-27HC Wainwright & Co.Buy
- 2026-04-23D. Boral CapitalBuy
- 2026-04-20D. Boral CapitalBuy
- 2026-03-24BTIGBuy
Recent news
- 2026-07-17NRXP Stock Price, Quote & Chart - ChartMill
- 2026-07-16Market Sentiment Around Loss-Making NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) - simplywall.st
- 2026-07-15Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation? - Yahoo Finance
- 2026-07-04Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
- 2026-07-03NRXP Should I Buy - Intellectia AI
- 2026-06-25NRXP Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-25NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE - GlobeNewswire
- 2026-06-24Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.